Literature DB >> 12544852

Migrainous vertigo: development of a pathogenetic model and structured diagnostic interview.

Joseph M Furman1, Dawn A Marcus, Carey D Balaban.   

Abstract

PURPOSE OF REVIEW: Vestibular symptoms occur frequently in patients with migraine. This review refines recently proposed diagnostic criteria for migraine-related vestibular symptoms, and develops a pathophysiological model for the interface between migraine and the vestibular system. RECENT
FINDINGS: The epidemiological link between migraine and vestibular symptoms and signs suggests shared pathogenetic mechanisms. Links between the vestibular nuclei, the trigeminal system, and thalamocortical processing centers provide the basis for the development of a pathophysiological model of migraine-related vertigo. During the last year, several studies have increased understanding of the relationship between migraine and vestibular symptoms. A study of motion sickness and allodynia in migraine patients supports the importance of central mechanisms of sensitization for migraine-related vestibular symptoms. A study has demonstrated effective treatment of vertigo with migraine therapy. The identification of migrainous vertigo, however, is hampered by a lack of standardized assessment criteria for both clinical and research practices. The application of published criteria for the diagnosis of migrainous vertigo allows the development of a standardized, structured assessment interview.
SUMMARY: An understanding of the relationship between migraine and the vestibular system increases knowledge of the pathogenesis of both migraine and vertigo. In addition, studies have identified successful treatment, with standard migraine therapies, of vestibular symptoms in patients with both migraine and vertigo. The use of a standardized assessment tool to identify this unique population of patients will help future studies to test both the pathological model and effective treatment options.

Entities:  

Mesh:

Year:  2003        PMID: 12544852     DOI: 10.1097/01.wco.0000053582.70044.e2

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  38 in total

1.  Current treatment of vestibular, ocular motor disorders and nystagmus.

Authors:  Michael Strupp; Thomas Brandt
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

2.  Three patients with migraine following caloric-induced vestibular stimulation.

Authors:  Barry Seemungal; Peter Rudge; Ros Davies; Michael Gresty; Adolfo Bronstein
Journal:  J Neurol       Date:  2006-04-10       Impact factor: 4.849

3.  Neurologic bases for comorbidity of balance disorders, anxiety disorders and migraine: neurotherapeutic implications.

Authors:  Carey D Balaban; Rolf G Jacob; Joseph M Furman
Journal:  Expert Rev Neurother       Date:  2011-03       Impact factor: 4.618

Review 4.  Neuronal P/Q-type calcium channel dysfunction in inherited disorders of the CNS.

Authors:  Sanjeev Rajakulendran; Diego Kaski; Michael G Hanna
Journal:  Nat Rev Neurol       Date:  2012-01-17       Impact factor: 42.937

5.  Dynamic tilt thresholds are reduced in vestibular migraine.

Authors:  Richard F Lewis; Adrian J Priesol; Keyvan Nicoucar; Koeun Lim; Daniel M Merfeld
Journal:  J Vestib Res       Date:  2011       Impact factor: 2.435

6.  Migraine Related Vertigo.

Authors:  Vithal D Udagatti; Rajendran Dinesh Kumar
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2017-02-04

Review 7.  Vestibular Migraine.

Authors:  Gülden Akdal
Journal:  Noro Psikiyatr Ars       Date:  2013-08-01       Impact factor: 1.339

Review 8.  Migraine-associated risks and comorbidity.

Authors:  H C Diener; M Küper; T Kurth
Journal:  J Neurol       Date:  2008-09-30       Impact factor: 4.849

Review 9.  [Vestibular migraine].

Authors:  T Lempert
Journal:  Nervenarzt       Date:  2009-08       Impact factor: 1.214

Review 10.  [Migrainous vertigo].

Authors:  M Von Brevern; G Arnold; T Lempert
Journal:  Schmerz       Date:  2004-10       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.